AR051675A1 - Derivados de 3-fenil-pirazol como moduladores del receptor 5-ht2a de la serotonina utiles para el tratamiento de trastornos relacionados con este - Google Patents
Derivados de 3-fenil-pirazol como moduladores del receptor 5-ht2a de la serotonina utiles para el tratamiento de trastornos relacionados con esteInfo
- Publication number
- AR051675A1 AR051675A1 ARP050104844A ARP050104844A AR051675A1 AR 051675 A1 AR051675 A1 AR 051675A1 AR P050104844 A ARP050104844 A AR P050104844A AR P050104844 A ARP050104844 A AR P050104844A AR 051675 A1 AR051675 A1 AR 051675A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- cycloalkyl
- alkenyl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos y sus composiciones farmacéuticas están dirigidos hacia métodos utiles en el tratamiento de la agregacion plaquetaria, arteriopatía, coronaria, infarto de miocardio, accidente isquémico transitorio, angina, accidente cerebrovascular, fibrilacion auricular, reduccion del riesgo de formacion de coágulos sanguíneos, asma o sus síntomas, agitacion o un síntoma, trastornos de la conducta, psicosis farmacogena, psicosis excitativa, síndrome de Gilles de la Tourette, trastorno maníaco, psicosis orgánico o sin especificacion, trastorno psicotico, psicosis, esquizofrenia agua, esquizofrenia cronica, esquizofrenia sin especificacion y trastornos relacionados, y trastornos del sueno, trastornos relacionados con la diabetes, leucoencefalopatía multifocal progresiva y semejantes. Reivindicacion 1: Un compuesto de formula (1), o una sal farmacéuticamente aceptable, hidrato o solvato de dicho compuesto; en donde: V es O, S, S(=O), S(=O)2 o NR10; W es C1-4 alquileno opcionalmente sustituido con 1 a 8 sustituyentes seleccionados independientemente entre el grupo integrado por C1-3 alquilo, C1-4 alcoxilo, carboxilo, ciano, C1-3 haloalquilo, halogeno y oxo, o W está ausente; X es C(=O), C(=S) o está ausente; Y es O, NR11 o está ausente; Z es C1-4 alquileno o C3-6 cicloalquileno, cada uno opcionalmente sustituido con 1 a 8 sustituyentes seleccionados independientemente entre el grupo integrado por C1-3 alquilo, C1-4 alcoxilo, carboxilo, ciano, C1-3 haloalquilo, halogeno, hidroxilo y oxo, o Z está ausente; R1 se selecciona del grupo integrado por H, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo y C3-7 cicloalquilo; R2 se selecciona del grupo integrado por H, C1-6 acilo, C1-6 aciloxilo, C2-6 alquenilo, C1-6 alcoxilo, C1-6 alquilo, C1-6 alquilcarboxamida, C2-6 alquinilo, C1-6 alquilsulfonamida, C1-6 alquilsulfinilo, C1-6 alquilsulfonilo, C1-6 alquiltio, C1-6 alquilureilo, amino, C1-6 alquilamino, C2-8 dialquilamino, carbo-C1-6-alcoxilo, carboxamida, carboxilo, ciano, C3-7 cicloalquilo, C2-8 dialquilcarboxamida, C2-8 dialquilsulfonamida, halogeno, C1-6 haloalcoxilo, C1-6 haloalquilo, C1-6 haloalquilsulfinilo, C1-6 haloalquilsulfonilo, C1-6 haloalquiltio, hidroxilo, tiol, nitro y sulfonamida; R3 se selecciona del grupo integrado por H, C2-6 alquenilo, C1-6 alquilo, C1-6 alquilcarboxamida, C2-6 alquinilo, C1-6 alquilsulfonamida, carbo-C1-6-alcoxilo, carboxamida, carboxilo, ciano, C3-7 cicloalquilo, C2-8 dialquilcarboxamida, halogeno, heteroarilo y fenilo; y en donde cada grupo C2-6 alquenilo, C1-6 alquilo, C2-6 alquinilo, C1-6 alquilsulfonamida, C3-7 cicloalquilo, heteroarilo y fenilo está opcionalmente sustituido con 1 a 5 sustituyentes seleccionados independientemente entre el grupo integrado por C1-5 acilo, C1-5 aciloxilo, C2-6 alquenilo, C1-4 alcoxilo, C1-8 alquilo, C1-6 alquilamino, C2-8 dialquilamino, C1-4 alquilcarboxamida, C2-6 alquinilo C1-4 alqulsulfonamida, C1-4 alquilsulfinilo, C1-4 alquilsulfonilo, C1-4 alquiltio, C1-4 alquilureilo, amino, carbo-C1-6-alcoxilo, carboxamida, carboxilo, ciano, C3-6 cicloalquilo, C2-6 dialquilcarboxamida, halogeno, C1-4 haloalcoxilo, C1-4 haloalquilo, C1-4 haloalquilsulfinilo, C1-4 haloalquilsulfonilo, C1-4 haloalquiltio, hidroxilo, nitro y sulfonamida; R4 es heterociclo, heterociclo, o heteroarilo, cada uno independientemente sustituido con sustituyentes seleccionados independientemente entre el grupo integrado por C1-6 acilo, C1-12 aciloxilo, C2-6 alquenilo, C1-4 alcoxilo,C1-6 alcoxicarbonilamino, C1-6 alquilo, C1-6 alquilamino, C2-8 dialquilamino, C1-4 alquilcarboxamida, C2-6 alquinilo, C1-4 alquilsulfonamida, C1-4 alquilsulfonilo, C1-4 alquilsulfonilo, C1-4 alquiltio, C1-4 alquilureilo, amino, carbo-C1-6-alcoxilo, carboxamida, carboxilo, ciano, C3-6 cicloalquilo, C3-7 cicloalquilcarbonilo, C2-6 dialquicarboxamida, formilo, halogeno, C1-4 haloalcoxilo, C1-4 haloalquilo, C1-4 haloalquilsulfinilo, C1-4 haloalquilsulfonilo, C1-4 haloalquiltio, heteroarilo, hidroxilo, nitro, fenilo y sulfonamida; en donde cada C1-5 acilo, C1-5 aciloxilo, C1-4 alcoxilo, C1-6 alquilo, C1-4 alquilcarboxamida, amino, carbo-C1-6-alcoxilo y heteroarilo está opcionalmente sustituido con sustituyentes seleccionados independientemente entre el grupo integrado por C1-6 alquilo, C1-5 acilo, C1-4 alcoxilo, C1-6 alquilamino, C2-8 dialquilamino, C1-4 alquilcarboxamida, C1-4 alquilsulfonilo, amino, carbo-C1-6-alcoxilo, carboxamida, carboxilo, ciano, C3-6 cicloalquilo, halogeno, C1-4 haloalcoxilo, C1-4 haloalquilo, hidroxilo y fenilo; R5, R6, y R7 se seleccionan independientemente del grupo integrado por H, C1-6 acilo, C1-6 aciloxilo, C2-6 alquenilo, C1-6 alcoxilo, C1-6 alquilo, C1-6 alquilcarboxamida, C2-6 alquinilo, C1-6 alquilsulfonamida, C1-6 alquilsulfinilo, C1-6 alquilsulfonilo, C1-6 alquiltio, C1-6 alquilureilo, amino, C1-6 alquilamino, C2-8 dialquilamino, C1-6 alquilimino, carbo-C1-6-alcoxilo, carboxamida, carboxilo, ciano, C3-7 cicloalquilo, C2-8 dialquilcarboxamida, C2-8 dialquilsulfonamida, halogeno, C1-6 haloalcoxilo, C1-6 haloalquilo, C1-6 haloalquilsulfinilo, C1-6 haloalquilsulfonilo, C1-6 haloalquiltio, heterociclo, hidroxilo, tiol, nitro, fenoxilo y fenilo; R8 es C1-8 alquilo, C2-6 alquenilo, arilo, C3-7 cicloalquilo o heteroarilo, cada uno opcionalmente sustituido con sustituyentes seleccionados independientemente entre el grupo integrado por C1-6 acilo, C1-6 aciloxilo, C2-6 alquenilo, C1-6 alcoxilo, C1-6 alquilo, C1-6 alquilcarboxamida, C2-6 alquinilo, C1-6 alquilsulfonamida, C1-6 alquilsulfinilo, C1-6 alquilsulfonilo, C1-6 alquiltio, C1-6 alquilureilo, amino, C1-6 alquilamino, C2-8 dialquilamino, C1-6 alquilimino, carbo-C1-6-alcoxilo, carboxamida, carboxilo, ciano, C3-7 cicloalquilo, C2-8 dialquilcarboxamida, C2-8 dialquilsulfonamida, halogeno, C1-6 haloalcoxilo, C1-6 haloalquilo, C1-6 haloalquilsulfinilo, C1-6 haloalquilsulfonilo, C1-6 haloalquiltio, heterociclo, hidroxilo, tiol, nitro, fenoxilo y fenilo, o dos sustituyentes adyacentes junto con dicho arilo o dicho heteroarilo forman un C5-7 cicloalquilo que opcionalmente comprende 1 a 2 átomos de oxígeno y opcionalmente está sustituido con F, Cl o Br; y en donde cada C2-6 alquenilo, C1-6 alquilo, C2-6 alquinilo, C1-6 alquilamino, C1-6 alquilimino, C2-8 dialquilamino, heterociclo y fenilo está opcionalmente sustituido con 1 a 5 sustituyentes seleccionados independientemente entre el grupo integrado por C1-6 acilo, C1-6 aciloxilo, C2-6 alquenilo, C1-6 alcoxilo, C1-6 alquilo, C1-6 alquilcarboxamida, C2-6 alquinilo, C1-6 alquilsulfonamida, C1-6 alquilsulfinilo, C1-6 alquilsulfonilo, C1-6 alquiltio, C1-6 alquilureilo, amino, C1-6 alquilamino, C2-8 dialquilamino, carbo-C1-6-alcoxilo, carboxamida, carboxilo, ciano, C3-7 cicloalquilo, C2-8 dialquilcarboxamida, halogeno, C1-6 haloalcoxilo, C1-6 haloalquilo, C1-6 haloalquilsulfinilo, C1-6 haloalquilsulfonilo, C1-6 haloalquiltio, hidroxilo, tiol y nitro; y R9, R10 y R11 son independientemente H o C1-8 alquilo; siempre que dicho compuesto no sea N-[4-oxiranilmetoxi-3-(2H-pirazol-3-il)-fenil]-acetamida.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62977404P | 2004-11-19 | 2004-11-19 | |
US64763905P | 2005-01-26 | 2005-01-26 | |
US65838405P | 2005-03-02 | 2005-03-02 | |
US71338405P | 2005-09-01 | 2005-09-01 | |
US73316505P | 2005-11-04 | 2005-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051675A1 true AR051675A1 (es) | 2007-01-31 |
Family
ID=36218810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104844A AR051675A1 (es) | 2004-11-19 | 2005-11-17 | Derivados de 3-fenil-pirazol como moduladores del receptor 5-ht2a de la serotonina utiles para el tratamiento de trastornos relacionados con este |
Country Status (37)
Country | Link |
---|---|
US (6) | US20070244086A1 (es) |
EP (2) | EP1978019A1 (es) |
JP (1) | JP5016494B2 (es) |
KR (2) | KR101275380B1 (es) |
CN (3) | CN103012378A (es) |
AR (1) | AR051675A1 (es) |
AT (1) | ATE407927T1 (es) |
AU (1) | AU2005307744C1 (es) |
BR (1) | BRPI0518446A2 (es) |
CA (1) | CA2588513C (es) |
CR (1) | CR9098A (es) |
CY (1) | CY1108508T1 (es) |
DE (1) | DE602005009748D1 (es) |
DK (1) | DK1833799T3 (es) |
EA (1) | EA011935B1 (es) |
ES (1) | ES2314750T3 (es) |
GT (1) | GT200500336A (es) |
HK (1) | HK1102818A1 (es) |
HN (1) | HN2005032627A (es) |
HR (1) | HRP20080592T3 (es) |
IL (1) | IL182945A (es) |
MA (1) | MA29081B1 (es) |
MX (1) | MX2007005959A (es) |
MY (1) | MY147684A (es) |
NI (1) | NI200700127A (es) |
NO (1) | NO340656B1 (es) |
NZ (1) | NZ554817A (es) |
PE (1) | PE20061130A1 (es) |
PL (1) | PL1833799T3 (es) |
PT (1) | PT1833799E (es) |
RS (1) | RS50698B (es) |
SA (1) | SA05260357B1 (es) |
SI (1) | SI1833799T1 (es) |
SV (1) | SV2008002307A (es) |
TN (1) | TNSN07188A1 (es) |
TW (2) | TWI409062B (es) |
WO (1) | WO2006055734A2 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE313532T1 (de) * | 2003-07-22 | 2006-01-15 | Arena Pharm Inc | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
CN1926114B (zh) * | 2004-03-23 | 2011-08-24 | 艾尼纳制药公司 | 用于制备经取代n-芳基-n′-′3-(1h-吡唑-5-基)苯基脲及其中间体的方法 |
SA05260357B1 (ar) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
MX2008014622A (es) * | 2006-05-18 | 2008-11-28 | Arena Pharm Inc | Formas cristalinas y procesos para la preparacion de fenil-pirazoles utiles como moduladores del receptor de serotonina 5-ht2a. |
USRE45336E1 (en) | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
CA2646076C (en) | 2006-05-18 | 2015-06-30 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
WO2008027483A1 (en) * | 2006-08-31 | 2008-03-06 | Arena Pharmaceuticals, Inc. | Benzofuran derivatives as modulators of the 5-ht2a receptor |
TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
WO2008054748A2 (en) * | 2006-10-31 | 2008-05-08 | Arena Pharmaceuticals, Inc. | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
ITMI20062230A1 (it) * | 2006-11-22 | 2008-05-23 | Acraf | Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende |
ES2421237T7 (es) | 2007-08-15 | 2013-09-30 | Arena Pharmaceuticals, Inc. | Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo |
AU2008334932B2 (en) | 2007-12-13 | 2014-05-22 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
CA2709104C (en) * | 2007-12-13 | 2017-06-13 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
ES2666324T3 (es) | 2008-10-28 | 2018-05-04 | Arena Pharmaceuticals, Inc. | Composiciones de un modulador del receptor de serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con el mismo |
US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10022263B2 (en) | 2011-07-14 | 2018-07-17 | Cook Medical Technologies Llc | Sling-based treatment of obstructive sleep apnea |
US10314736B2 (en) | 2012-10-16 | 2019-06-11 | Cook Medical Technologies Llc | Method and apparatus for treating obstructive sleep apnea (OSA) |
WO2015017749A1 (en) | 2013-08-01 | 2015-02-05 | Mohan P Arun | Tissue adjustment implant |
CN105392433B (zh) | 2013-08-05 | 2019-02-19 | 库克医学技术有限责任公司 | 具有可释放管状构件的医疗装置及其使用方法 |
EP2898920B1 (en) | 2014-01-24 | 2018-06-06 | Cook Medical Technologies LLC | Articulating balloon catheter |
US9974563B2 (en) | 2014-05-28 | 2018-05-22 | Cook Medical Technologies Llc | Medical devices having a releasable member and methods of using the same |
US9913661B2 (en) | 2014-08-04 | 2018-03-13 | Cook Medical Technologies Llc | Medical devices having a releasable tubular member and methods of using the same |
WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
CN108472285A (zh) | 2015-07-15 | 2018-08-31 | 阿速万科学有限责任公司 | 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物 |
CN111093572A (zh) | 2017-06-29 | 2020-05-01 | 库克医学技术有限责任公司 | 用于重新定位组织的可植入医疗装置 |
WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
EP3710441A1 (en) | 2017-11-17 | 2020-09-23 | Hepagene Therapeutics, Inc. | Urea derivatives as inhibitors of ask1 |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
EP3731749A4 (en) | 2017-12-31 | 2022-07-27 | Neuroenhancement Lab, LLC | NEURO-ACTIVATION SYSTEM AND METHOD FOR ENHANCING EMOTIONAL RESPONSE |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
CN113382683A (zh) | 2018-09-14 | 2021-09-10 | 纽罗因恒思蒙特实验有限责任公司 | 改善睡眠的***和方法 |
TW202241446A (zh) * | 2020-12-31 | 2022-11-01 | 美商艾尼納製藥公司 | 治療方法 |
WO2023122135A1 (en) * | 2021-12-22 | 2023-06-29 | Kuleon Llc | Serotonin receptor agonists and methods of making and using the same |
WO2024122617A1 (ja) * | 2022-12-08 | 2024-06-13 | 塩野義製薬株式会社 | セロトニン受容体結合活性を有する含窒素複素環および炭素環誘導体 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4099012A (en) * | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
DE2926517A1 (de) | 1979-06-30 | 1981-01-15 | Beiersdorf Ag | Substituierte 3-aryl-pyrazole und 5-aryl-isoxazole und verfahren zu ihrer herstellung |
DE2928485A1 (de) * | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
US4985352A (en) * | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
US5661024A (en) | 1989-10-31 | 1997-08-26 | Synaptic Pharmaceutical Corporation | DNA encoding a human serotonic (5-HT2) receptor and uses thereof |
US5077409A (en) * | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
US5128351A (en) * | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
FR2682379B1 (fr) * | 1991-10-09 | 1994-02-11 | Rhone Poulenc Agrochimie | Nouveaux phenylpyrazoles fongicides. |
FR2690440B1 (fr) * | 1992-04-27 | 1995-05-19 | Rhone Poulenc Agrochimie | Arylpyrazoles fongicides. |
DE69411176T2 (de) * | 1993-08-20 | 1998-11-12 | Smithkline Beecham Plc | Amide und harnstoffderivate als 5ht1d rezeptor antagonisten |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
FR2722369B1 (fr) | 1994-07-13 | 1998-07-10 | Rhone Poulenc Agrochimie | Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides |
EP0784612A1 (en) | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
KR19980701879A (ko) * | 1995-02-02 | 1998-06-25 | 피터 기딩스 | 5-히드록시트립타민 수용체 길항제로서의 인돌 유도체 |
JPH11503110A (ja) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体拮抗剤 |
AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
US6054472A (en) * | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US6005008A (en) * | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
GB9607219D0 (en) * | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
AU2962297A (en) | 1996-05-24 | 1998-01-05 | Neurosearch A/S | Phenyl derivatives useful as blockers of chloride channels |
DE69716424T2 (de) * | 1996-05-24 | 2003-02-20 | Neurosearch A/S, Ballerup | Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker |
PL330849A1 (en) * | 1996-06-27 | 1999-06-07 | Smithkline Beecham Corp | Antagonists of il-8 receptors |
JP2001508767A (ja) * | 1996-12-02 | 2001-07-03 | 藤沢薬品工業株式会社 | 5―ht拮抗作用を有するインドール―ウレア誘導体 |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
US6541209B1 (en) | 1997-04-14 | 2003-04-01 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6696475B2 (en) * | 1997-04-22 | 2004-02-24 | Neurosearch A/S | Substituted phenyl derivatives, their preparation and use |
BR9808938A (pt) * | 1997-04-22 | 2000-08-01 | Neurosearch As | Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto |
EP1000017A4 (en) | 1997-07-29 | 2000-10-18 | Smithkline Beecham Corp | ANTAGONISTS OF THE IL-8 RECEPTOR |
AU748041B2 (en) * | 1997-10-31 | 2002-05-30 | Aventis Pharma Limited | Substituted anilides |
US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
JP3887769B2 (ja) | 1997-12-22 | 2007-02-28 | バイエル コーポレイション | 対称および非対称ジフェニル尿素を用いるp38キナーゼの阻害 |
KR100704977B1 (ko) | 1997-12-22 | 2007-04-09 | 바이엘 코포레이션 | 대칭성 및 비대칭성 치환디페닐우레아를 이용한 raf키나제의 저해 |
ES2156845T1 (es) | 1998-04-14 | 2001-08-01 | Arena Pharm Inc | Receptores de serotonina humana no endogenos constitutivamente activados y moduladores de moleculas pequeñas para estos. |
US6140509A (en) * | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
GB9816263D0 (en) * | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
AP2001002103A0 (en) * | 1998-10-22 | 2001-03-31 | Neurosearch As | Substituted phenyl derivatives, their preparation and use. |
US6150393A (en) | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
IL145508A0 (en) | 1999-03-26 | 2002-06-30 | Euro Celtique Sa | Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same |
GB9909409D0 (en) | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
US6531291B1 (en) * | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
EP1108720A1 (en) | 1999-12-08 | 2001-06-20 | Basf Aktiengesellschaft | Herbicidal 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dines |
FR2810979B1 (fr) * | 2000-06-29 | 2002-08-23 | Adir | Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2002039987A2 (en) | 2000-11-14 | 2002-05-23 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
AR035521A1 (es) | 2000-12-22 | 2004-06-02 | Lundbeck & Co As H | Derivados de 3-indolina y composicion farmaceutica que los comprende |
WO2002076464A1 (en) | 2001-03-22 | 2002-10-03 | Arena Pharmaceuticals, Inc. | Anti-psychosis combination |
CN104744461A (zh) * | 2001-09-21 | 2015-07-01 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
WO2003062206A2 (en) * | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
AU2003275093A1 (en) | 2002-09-24 | 2004-04-19 | Arena Pharmaceuticals, Inc. | Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof |
AU2003290638A1 (en) | 2002-11-08 | 2004-06-03 | Interdigital Technology Corporation | Composite channel quality estimation techniques for wireless receivers |
US20060229335A1 (en) * | 2002-12-24 | 2006-10-12 | Bradley Teegarden | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
CA2515544A1 (en) | 2003-02-11 | 2004-08-26 | Kemia Inc. | Compounds for the treatment of viral infection |
JP2006521345A (ja) | 2003-03-28 | 2006-09-21 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 |
GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
ATE313532T1 (de) * | 2003-07-22 | 2006-01-15 | Arena Pharm Inc | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
US20050054691A1 (en) * | 2003-08-29 | 2005-03-10 | St. Jude Children's Research Hospital | Carboxylesterase inhibitors |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
CN1926114B (zh) * | 2004-03-23 | 2011-08-24 | 艾尼纳制药公司 | 用于制备经取代n-芳基-n′-′3-(1h-吡唑-5-基)苯基脲及其中间体的方法 |
WO2006004722A2 (en) * | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
EP1786422A2 (en) | 2004-08-16 | 2007-05-23 | Prosidion Limited | Aryl urea derivatives for treating obesity |
US20060063754A1 (en) * | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
WO2006045010A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
JP2008518014A (ja) | 2004-10-27 | 2008-05-29 | ニューロゲン コーポレイション | Cb1拮抗薬としてのジアリール尿素 |
WO2006049734A2 (en) | 2004-10-29 | 2006-05-11 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
SA05260357B1 (ar) * | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
AR051978A1 (es) | 2004-12-01 | 2007-02-21 | Divergence Inc | Composiciones plaguicidas y metodos |
US20080015223A1 (en) * | 2004-12-03 | 2008-01-17 | Arena Pharmaceuticals, Inc. | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto |
EP1831172B1 (en) | 2004-12-28 | 2009-02-18 | Council of Scientific and Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
US7625931B2 (en) | 2005-01-14 | 2009-12-01 | Cgi Pharmaceuticals, Inc. | Certain substituted diphenyl ureas, as modulators of kinase activity |
CN101160127A (zh) * | 2005-01-19 | 2008-04-09 | 艾尼纳制药公司 | 用于预防或治疗进行性多灶性白质脑病而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物 |
AR052886A1 (es) | 2005-01-26 | 2007-04-11 | Arena Pharm Inc | Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis |
WO2006079637A1 (en) | 2005-01-27 | 2006-08-03 | Janssen Pharmaceutica N.V. | Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders |
GT200600042A (es) | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
WO2006089871A2 (en) | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
GB0505437D0 (en) | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
GB0505725D0 (en) | 2005-03-19 | 2005-04-27 | Merck Sharp & Dohme | Therapeutic agents |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
ES2341127T3 (es) | 2005-04-26 | 2010-06-15 | Hypnion, Inc. | Compuestos de bencisoxazol-piperazina y procedimiento de uso. |
EP1734039A1 (en) | 2005-06-13 | 2006-12-20 | Esbatech AG | Aryl urea compounds as BETA-secretase inhibitors |
KR101363278B1 (ko) | 2005-06-27 | 2014-02-21 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | 이미다졸계 lxr 변조제 |
US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
WO2007120600A2 (en) | 2006-04-10 | 2007-10-25 | Arena Pharmaceuticals, Inc. | 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
GB0608655D0 (en) | 2006-05-03 | 2006-06-14 | Merck Sharp & Dohme | Therapeutic Treatment |
CA2646076C (en) * | 2006-05-18 | 2015-06-30 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
MX2008014622A (es) | 2006-05-18 | 2008-11-28 | Arena Pharm Inc | Formas cristalinas y procesos para la preparacion de fenil-pirazoles utiles como moduladores del receptor de serotonina 5-ht2a. |
USRE45336E1 (en) * | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
WO2007136875A2 (en) | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Acetamide derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
WO2008027483A1 (en) | 2006-08-31 | 2008-03-06 | Arena Pharmaceuticals, Inc. | Benzofuran derivatives as modulators of the 5-ht2a receptor |
TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
WO2008054748A2 (en) | 2006-10-31 | 2008-05-08 | Arena Pharmaceuticals, Inc. | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
ES2421237T7 (es) | 2007-08-15 | 2013-09-30 | Arena Pharmaceuticals, Inc. | Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo |
JP2009196349A (ja) * | 2008-01-25 | 2009-09-03 | Canon Finetech Inc | バーコード印刷装置およびバーコード印刷方法 |
US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
-
2005
- 2005-11-16 SA SA05260357A patent/SA05260357B1/ar unknown
- 2005-11-16 PE PE2005001343A patent/PE20061130A1/es active IP Right Grant
- 2005-11-17 PT PT05849546T patent/PT1833799E/pt unknown
- 2005-11-17 BR BRPI0518446-0A patent/BRPI0518446A2/pt not_active Application Discontinuation
- 2005-11-17 CA CA2588513A patent/CA2588513C/en not_active Expired - Fee Related
- 2005-11-17 CN CN2012105332199A patent/CN103012378A/zh active Pending
- 2005-11-17 EP EP08010784A patent/EP1978019A1/en not_active Withdrawn
- 2005-11-17 MX MX2007005959A patent/MX2007005959A/es active IP Right Grant
- 2005-11-17 US US11/597,306 patent/US20070244086A1/en not_active Abandoned
- 2005-11-17 CN CN2005800392789A patent/CN101084195B/zh not_active Expired - Fee Related
- 2005-11-17 KR KR1020077013740A patent/KR101275380B1/ko active IP Right Grant
- 2005-11-17 NZ NZ554817A patent/NZ554817A/en not_active IP Right Cessation
- 2005-11-17 RS RSP-2008/0443A patent/RS50698B/sr unknown
- 2005-11-17 DK DK05849546T patent/DK1833799T3/da active
- 2005-11-17 SI SI200530504T patent/SI1833799T1/sl unknown
- 2005-11-17 EA EA200701101A patent/EA011935B1/ru not_active IP Right Cessation
- 2005-11-17 JP JP2007543250A patent/JP5016494B2/ja active Active
- 2005-11-17 KR KR1020137001609A patent/KR20130027039A/ko not_active Application Discontinuation
- 2005-11-17 ES ES05849546T patent/ES2314750T3/es active Active
- 2005-11-17 CN CN201210532179.6A patent/CN102977029B/zh not_active Expired - Fee Related
- 2005-11-17 MY MYPI20055376A patent/MY147684A/en unknown
- 2005-11-17 EP EP05849546A patent/EP1833799B1/en active Active
- 2005-11-17 WO PCT/US2005/041726 patent/WO2006055734A2/en active Application Filing
- 2005-11-17 GT GT200500336A patent/GT200500336A/es unknown
- 2005-11-17 AR ARP050104844A patent/AR051675A1/es active IP Right Grant
- 2005-11-17 AU AU2005307744A patent/AU2005307744C1/en not_active Ceased
- 2005-11-17 PL PL05849546T patent/PL1833799T3/pl unknown
- 2005-11-17 AT AT05849546T patent/ATE407927T1/de active
- 2005-11-17 DE DE602005009748T patent/DE602005009748D1/de active Active
- 2005-11-18 HN HN2005032627A patent/HN2005032627A/es unknown
- 2005-11-18 SV SV2005002307A patent/SV2008002307A/es unknown
- 2005-11-18 TW TW101110198A patent/TWI409062B/zh not_active IP Right Cessation
- 2005-11-18 TW TW094140731A patent/TWI377059B/zh not_active IP Right Cessation
-
2006
- 2006-11-20 US US11/602,164 patent/US7884101B2/en active Active
-
2007
- 2007-05-02 IL IL182945A patent/IL182945A/en active IP Right Grant
- 2007-05-04 CR CR9098A patent/CR9098A/es unknown
- 2007-05-16 TN TNP2007000188A patent/TNSN07188A1/fr unknown
- 2007-05-17 NI NI200700127A patent/NI200700127A/es unknown
- 2007-05-30 MA MA29958A patent/MA29081B1/fr unknown
- 2007-06-11 NO NO20072986A patent/NO340656B1/no not_active IP Right Cessation
- 2007-10-18 HK HK07111337A patent/HK1102818A1/xx not_active IP Right Cessation
-
2008
- 2008-11-13 CY CY20081101299T patent/CY1108508T1/el unknown
- 2008-11-18 HR HR20080592T patent/HRP20080592T3/xx unknown
-
2010
- 2010-12-22 US US12/976,887 patent/US20110105456A1/en not_active Abandoned
-
2012
- 2012-09-14 US US13/616,842 patent/US8785441B2/en active Active
-
2016
- 2016-04-25 US US15/137,228 patent/US20160304463A1/en not_active Abandoned
-
2018
- 2018-11-01 US US16/177,672 patent/US10781180B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051675A1 (es) | Derivados de 3-fenil-pirazol como moduladores del receptor 5-ht2a de la serotonina utiles para el tratamiento de trastornos relacionados con este | |
AR063100A1 (es) | Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los trastornos relacionados con dicho receptor | |
AR045069A1 (es) | Derivados de pirazol-fenil urea como moduladores del receptor 5ht 2a de serotonina, utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo | |
AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
CN106986857B (zh) | Trk抑制化合物 | |
ES2481408T3 (es) | Derivados sustituidos de indolilalquilaminas como inhibidores de histona-desacetilasas | |
PE20120655A1 (es) | Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map) | |
CA2825172A1 (en) | Indole derivative and pharmacologically acceptable salt of same | |
ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
HUE025419T2 (en) | Heteroaryl-substituted 1,3-dihydro-indol-2-one derivatives and medicaments containing them | |
BRPI1008376B1 (pt) | Quinazolinonas como inibidores de prolil hidroxilase | |
AR074676A1 (es) | Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa. | |
AR078497A1 (es) | Isoxazoles como antagonistas de los receptores de acido lisofosfatidico | |
PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
PE20091925A1 (es) | Derivados de indazol sustituidos con fenilo o benzodioxinilo | |
AR064635A1 (es) | Derivados de benzotiazolona | |
AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
AR065804A1 (es) | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento | |
WO2012102254A1 (ja) | インドール誘導体、またはその薬理学的に許容される塩 | |
PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
AR082109A1 (es) | Derivados de bipiridilo | |
AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |